

May 5, 2021



# Trevena to Release First Quarter 2021 Financial Results on May 6, 2021

**Company to host conference call on May 6, 2021, at 8:00 a.m. ET**

CHESTERBROOK, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- **Trevena, Inc. (Nasdaq: TRVN)**, a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2021, prior to the market open on Thursday, May 6, 2021.

Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. ET on the same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Bob Yoder, SVP and Chief Commercial Officer, Mark Demitrack, SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Officer.

**Title:** Trevena First Quarter 2021 Financial Results Conference Call & Webcast

**Date:** Thursday, May 6, 2021

**Time:** 8:00 a.m. ET

**Conference Call Details:** Toll-Free: 855-465-0180  
International: 484-756-4313  
Conference ID: 3884579

The conference call will be webcast live from the company's website and will be available via the following links:

**Webcast:** <https://www.trevena.com/investors/events-presentations/ir-calendar>  
<https://edge.media-server.com/mmc/p/7iphx7qe>

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the company's website.

## About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company's novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for

maintenance treatment of opioid use disorder, TRV045 for epilepsy and chronic neuropathic pain, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.

For more information, please visit [www.Trevena.com](http://www.Trevena.com).

**Investor Contact:**

Dan Ferry  
Managing Director  
LifeSci Advisors, LLC  
[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)  
(617) 430-7576

**PR & Media Contact:**

Sasha Bennett  
Director  
Clyde Group  
[Sasha.Bennett@clydegroupp.com](mailto:Sasha.Bennett@clydegroupp.com)  
(239) 248-3409



Source: Trevena Inc.